Reta face is the new Ozempic face according to dermatologists tracking rapid body transformations.
Patients taking triple-agonist drugs experience faster weight loss than those using standard GLP-1 medications, leaving underlying facial skin with less time to adjust to sudden volume loss.
Eli Lilly develops retatrutide, a drug often called the Godzilla of weight-loss medications by online users. Initial trial results show the compound more than double the weight loss patients experience on Ozempic.
Drugs like Ozempic and Wegovy act as glucagon-like peptide-1 receptor agonists. Medications such as Mounjaro and Zepbound combine GLP-1 and glucose-dependent insulinotropic polypeptide receptors.
Retatrutide activates three separate receptors including glucagon alongside GLP-1 and GIP. Eli Lilly plans to submit its application for regulatory review to the U.S. Food and Drug Administration in early 2027.
Some individuals purchase grey-market versions of the drug before official approval. These users post their physical transformations online, documenting both body changes and facial alterations.
“Reta face is the new Ozempic face,” said Gary Goldenberg, a dermatologist, told Men’s Health.
“Since retatrutide is a triple biologic agonist that produces more significant weight loss than GLP peptides, patients may have an even more exaggerated appearance of a sunken, aged look,” Goldenberg told Men’s Health.
“Facial bones can also become more prominent as fat disappears. The skin can thin, as collagen and elastic fibers have less underlying fat plumping them up,” Goldenberg told Men’s Health.
Plastic surgery demand surges as patients seek treatments for loose skin and facial volume loss. GLP-1s are probably the single most powerful factor behind plastic surgery these days, Dr. Daniel Gould told The Looker in May.
I believe that about 70 to 80 percent of my patients are currently on those medications, Dr. Daniel Gould said.
Eli Lilly plans to apply for U.S. Food and Drug Administration review in early 2027. The regulatory agency has not yet evaluated the medication.
Retatrutide activates three receptors including glucagon, GIP, and GLP-1. Initial results indicate it delivers more than double the weight loss of Ozempic’s highest approved dose.
Weight-loss experts told Men’s Health that the primary method to prevent dramatic facial changes is to shed excess pounds gradually rather than rapidly.
Related reading